Dr. Korde is currently a research scientist in Discovery Therapeutics department of Shire Pharmaceuticals, Lexington, MA. At Shire, she is heavily involved in core analytical expertise on early stage biochemical/biophysical characterization of pipeline drug candidates. Dr.Korde earned her PhD in Biochemistry/Drug Discovery from Northeastern University in Boston MA in May 2017. Her graduate research was focused on expression, purification and bioanalytical characterization of Human Cannabinoid Receptor 1 (hCB1), an important target receptor present in human brains. She also played a key role in our collaborative efforts with Dr. Raymond Stevens’s group based out of Scripps, La Jolla CA and they were the first ones to crystallize hCB1 receptors, and the results were recently published in top-tier Cell, and Nature Journal. In addition to analytical chemistry, Dr. Korde also has a strong cellular biology/Pharmacology background from her work with eminent scientist-Dr.Bruce Spiegelman in Harvard Medical School, were the group was first to discover the beneficial effects of exercise induced hormone Irisin which is released after moderated endurance aerobic activity. Dr. Korde has many high-impact publications in top-tier journals and also serves as reviewer for expertise in her field.

Dr. Korde is interested in molecular and cellular pharmacology, functional as well as structural (biochemical, biophysical) characterization of biopharmaceuticals, gene therapy and immuno-oncology.